Literature DB >> 3180983

Increased parietal cell responsiveness to tetragastrin in patients with recurrent duodenal ulcer.

A Yanaka1, H Muto.   

Abstract

To clarify the contributive factors in the recurrence of duodenal ulcer, the present study was carried out on 65 male patients with active duodenal ulcers and 20 healthy male subjects. After having verified that the ulcer had healed, gastric acid secretory responses to graded doses of tetragastrin from 62.5 to 16,000 ng/kg/hr were investigated using a logarithmic transformation model. Several clinical features were also investigated. The patients were divided into three groups based on the later endoscopic follow-up study for two years. The early-recurrent group included 16 patients with recurrence occurring within three months. The late-recurrent group included 25 with recurrence occurring after three months. The nonrecurrent group included 24 patients without recurrences during the follow-up period. The 20 healthy male subjects were defined as a control group. The results were as follows: (1) Significant differences were not discerned either in basal and peak acid outputs between the three patients groups. (2) The ED50 value for tetragastrin was lower in the early-recurrent group than in the other three groups. (3) The early-recurrent group showed a higher percentage of smokers than the other patient groups. These results suggest that smoking and increased parietal cell responsiveness correlates strongly with duodenal ulcer recurrence.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3180983     DOI: 10.1007/bf01537003

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  29 in total

1.  Effect of smoking on gastric secretion.

Authors:  D W PIPER; J M RAINE
Journal:  Lancet       Date:  1959-04-04       Impact factor: 79.321

2.  Increased gastric secretory capacity in smokers without gastrointestinal lesions.

Authors:  S Massarrat; F Enschai; P M Pittner
Journal:  Gut       Date:  1986-04       Impact factor: 23.059

3.  Cigarettes, alcohol, coffee and peptic ulcer.

Authors:  G D Friedman; A B Siegelaub; C C Seltzer
Journal:  N Engl J Med       Date:  1974-02-28       Impact factor: 91.245

4.  Maximal histalog test in control subjects and patients with peptic ulcer.

Authors:  K G Wormsley; M I Grossman
Journal:  Gut       Date:  1965-10       Impact factor: 23.059

5.  Smoking impairs therapeutic gastric inhibition.

Authors:  E J Boyd; J A Wilson; K G Wormsley
Journal:  Lancet       Date:  1983-01-15       Impact factor: 79.321

6.  Effects of nicotine on gastrointestinal secretions..

Authors:  S J Konturek; T E Solomon; W G McCreight; L R Johnson; E D Jacobson
Journal:  Gastroenterology       Date:  1971-06       Impact factor: 22.682

7.  Pentagastrin dose-response in peptic ulcer disease.

Authors:  H Petersen; J Myren
Journal:  Scand J Gastroenterol       Date:  1975       Impact factor: 2.423

8.  Parietal cell responsiveness in duodenal ulcer.

Authors:  K G Wormsley; M P Mahoney
Journal:  Br Med J       Date:  1967-02-04

9.  Effect of nicotine on gastric mucosal blood flow and acid secretion.

Authors:  A Sonnenberg; N Hüsmert
Journal:  Gut       Date:  1982-06       Impact factor: 23.059

10.  Sensitivity of the parietal cell to pentagastrin in health and duodenal ulcer disease: a reappraisal.

Authors:  F Halter; U Bangerter; W H Häcki; M Schlup; L Varga; S Wyder; A Rotzer; R Galeazzi
Journal:  Scand J Gastroenterol       Date:  1982-06       Impact factor: 2.423

View more
  3 in total

Review 1.  Optimizing acid suppression for treatment of acid-related diseases.

Authors:  R H Hunt; C Cederberg; J Dent; F Halter; C Howden; I N Marks; S Rune; R P Walt
Journal:  Dig Dis Sci       Date:  1995-02       Impact factor: 3.199

2.  Changes in nocturnal and peak acid outputs after duodenal ulcer healing with sucralfate or ranitidine.

Authors:  A F Kummer; D A Johnston; I N Marks; G O Young; N A Tigler-Wybrandi; S A Bridger
Journal:  Gut       Date:  1992-02       Impact factor: 23.059

Review 3.  The H2-receptor antagonist era in duodenal ulcer disease.

Authors:  I N Marks
Journal:  Yale J Biol Med       Date:  1992 Nov-Dec
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.